On Monday and Tuesday of this week, CBI's 9th Forum on Patient Reported Outcomes was held in Philadelphia. The expert presenters from pharma, CROs, service providers and academic health centers covered a variety of topics on how to ensure the validity of PRO concepts, patient data and new technologies.
The co-chairs of the event, Ari Gnanasakthy, Executive Director, HE&OR, Novartis, and Susan Vallow, Director for Patient Reported Outcomes at Janssen Global Services, LLC, noted the following emerging themes from the conference as important to the PRO audience in the upcoming months: FDA/EMA regulations; increasing use of PRO in the post-registration environment; how best to use PRO as a quality measure; mixed modality usage and how new collaborative initiatives across the industry are being used to combat inefficiencies in development and how they impact PROs.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.